New Emerging Targets in Cancer Immunotherapy: CD27 (TNFRSF7)

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2020 Mar 11

PMID 32152062

Citations 80

Authors

Angelika M Starzer

Anna S Berghoff

Affiliations

Soon will be listed here.

Abstract

Cluster of differentiation 27 (CD27) is a member of the tumour necrosis factor receptor superfamily and plays a key role in T-cell activation by providing a costimulatory signal. Bound to its natural ligand CD70, CD27 signalling enhances T-cell proliferation and differentiation to effector and memory T cells and therefore has potential as an immune modulatory target in cancer treatment. The CD27 agonistic antibody varlilumab showed promising efficacy in haematological as well as solid cancers. Current studies investigate the combination of the CD27 agonistic antibody varlilumab in combination with the PD1 axis targeting immune checkpoint inhibitors like nivolumab or atezolizumab. Further, CD70 expression is used as a therapeutic target for ADCs, antibodies inducing ADCC, as well as the immunological target for chimeric antigen receptor gene-modified T cells and specific dendritic cell vaccination. In line with this, targeting the CD27 axis was shown to be feasible and safe in early clinical trials with the most commonly occurring side effects being thrombocytopenia, fatigue and nausea. In this mini review, we aimed to elucidate the immunobiology of CD27 and its potential as a target in cancer immunotherapy.

Citing Articles

A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance.

Fu C, Sun L, Feng C, Zhou T, Bi Y Front Oncol. 2025; 15:1464578.

PMID: 40040723 PMC: 11876053. DOI: 10.3389/fonc.2025.1464578.

Leukocyte-specific protein 1 is associated with the stage and tumor immune infiltration of cervical cancer.

Xu D, Zhou X, Min S, Zhang Y, Zhu X, Qiao K Sci Rep. 2025; 15(1):7566.

PMID: 40038352 PMC: 11880245. DOI: 10.1038/s41598-025-91066-0.

Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.

Alden S, Charmsaz S, Li H, Tsai H, Danilova L, Munjal K J Immunother Cancer. 2025; 13(1).

PMID: 39832896 PMC: 11748946. DOI: 10.1136/jitc-2024-009734.

Activated CD27PD-1 CD8 T Cells and CD4 T Regulatory Cells Dominate the Tumor Microenvironment in Refractory Celiac Disease Type II.

Dieckman T, Schreurs M, Lindelauf C, Mahfouz A, Meijer C, Pigeaud L Gastro Hep Adv. 2025; 4(1):100545.

PMID: 39802487 PMC: 11719358. DOI: 10.1016/j.gastha.2024.08.023.

Dissecting the genetic basis and mechanisms underlying the associations between multiple extrahepatic factors and autoimmune liver diseases.

Zhang Z, Zhang J, Yan X, Wang J, Huang H, Teng M J Transl Autoimmun. 2025; 10:100260.

PMID: 39741931 PMC: 11683281. DOI: 10.1016/j.jtauto.2024.100260.

References

Wajant H . Therapeutic targeting of CD70 and CD27. Expert Opin Ther Targets. 2016; 20(8):959-73. DOI: 10.1517/14728222.2016.1158812. View

Ryan M, Kostner H, Gordon K, Duniho S, Sutherland M, Yu C . Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010; 103(5):676-84. PMC: 2938259. DOI: 10.1038/sj.bjc.6605816. View

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M . Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clin Cancer Res. 2017; 23(21):6411-6420. DOI: 10.1158/1078-0432.CCR-17-0613. View

Arens R, Schepers K, Nolte M, van Oosterwijk M, van Lier R, Schumacher T . Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med. 2004; 199(11):1595-605. PMC: 2211777. DOI: 10.1084/jem.20031111. View

Yamada S, Shinozaki K, Agematsu K . Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol. 2002; 130(3):424-30. PMC: 1906551. DOI: 10.1046/j.1365-2249.2002.02012.x. View

Croft M . Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol. 2003; 3(8):609-20. DOI: 10.1038/nri1148. View

Ramakrishna V, Sundarapandiyan K, Zhao B, Bylesjo M, Marsh H, Keler T . Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J Immunother Cancer. 2015; 3:37. PMC: 4619281. DOI: 10.1186/s40425-015-0080-2. View

Abolhassani H, Edwards E, Ikinciogullari A, Jing H, Borte S, Buggert M . Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 2016; 214(1):91-106. PMC: 5206499. DOI: 10.1084/jem.20160849. View

Law C, Gordon K, Toki B, Yamane A, Hering M, Cerveny C . Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006; 66(4):2328-37. DOI: 10.1158/0008-5472.CAN-05-2883. View

10.

He L, Prostak N, Thomas L, Vitale L, Weidlick J, Crocker A . Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 2013; 191(8):4174-83. DOI: 10.4049/jimmunol.1300409. View

11.

Massard C, Soria J, Krauss J, Gordon M, Lockhart A, Rasmussen E . First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemother Pharmacol. 2019; 83(6):1057-1063. DOI: 10.1007/s00280-019-03796-4. View

12.

Tannir N, Forero-Torres A, Ramchandren R, Pal S, Ansell S, Infante J . Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014; 32(6):1246-57. DOI: 10.1007/s10637-014-0151-0. View

13.

Yang Z, Grote D, Xiu B, Ziesmer S, Price-Troska T, Hodge L . TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia. 2014; 28(9):1872-84. PMC: 4145058. DOI: 10.1038/leu.2014.84. View

14.

Tesselaar K, Arens R, van Schijndel G, Baars P, van der Valk M, Borst J . Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2002; 4(1):49-54. DOI: 10.1038/ni869. View

15.

Taraban V, Rowley T, Kerr J, Willoughby J, Johnson P, Al-Shamkhani A . CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization. Eur J Immunol. 2013; 43(12):3314-23. DOI: 10.1002/eji.201343579. View

16.

Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman S, Morimoto C . CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci U S A. 1995; 92(24):11249-53. PMC: 40609. DOI: 10.1073/pnas.92.24.11249. View

17.

Phillips T, Barr P, Park S, Kolibaba K, Caimi P, Chhabra S . A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2018; 37(2):297-306. PMC: 6440937. DOI: 10.1007/s10637-018-0655-0. View

18.

Pen J, De Keersmaecker B, Maenhout S, Van Nuffel A, Heirman C, Corthals J . Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol. 2013; 191(4):1976-83. DOI: 10.4049/jimmunol.1201008. View

19.

Morimoto S, Kanno Y, Tanaka Y, Tokano Y, Hashimoto H, Jacquot S . CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol. 2001; 164(8):4097-104. DOI: 10.4049/jimmunol.164.8.4097. View

20.

Wilgenhof S, Van Nuffel A, Benteyn D, Corthals J, Aerts C, Heirman C . A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013; 24(10):2686-2693. DOI: 10.1093/annonc/mdt245. View